1. Home
  2. ROMA vs XOMA Comparison

ROMA vs XOMA Comparison

Compare ROMA & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Roma Green Finance Limited

ROMA

Roma Green Finance Limited

HOLD

Current Price

$8.11

Market Cap

503.9M

Sector

Finance

ML Signal

HOLD

Logo XOMA Corporation

XOMA

XOMA Corporation

HOLD

Current Price

$41.91

Market Cap

471.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ROMA
XOMA
Founded
2018
1981
Country
Hong Kong
United States
Employees
N/A
14
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
503.9M
471.6M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
ROMA
XOMA
Price
$8.11
$41.91
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$52.50
AVG Volume (30 Days)
46.0K
91.2K
Earning Date
12-23-2025
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$24.59
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$29.64
Revenue Growth
N/A
N/A
52 Week Low
$1.16
$22.29
52 Week High
$11.77
$42.81

Technical Indicators

Market Signals
Indicator
ROMA
XOMA
Relative Strength Index (RSI) 58.24 59.80
Support Level $6.01 $37.00
Resistance Level $8.53 $42.25
Average True Range (ATR) 0.96 0.36
MACD 0.12 -0.16
Stochastic Oscillator 55.48 48.48

Price Performance

Historical Comparison
ROMA
XOMA

About ROMA Roma Green Finance Limited

Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.

About XOMA XOMA Corporation

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.

Share on Social Networks: